MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment of the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to block the uptake of dietary phenylalanine.

The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.

Recently, as a spin-off of the PKU drug project and using the Phe-binding MIPs, MipSalus has initiated development of a home sensor allowing PKU patients to monitor their disease and swiftly adjust food and medication.

MipSalus has facilities and laboratories in the research park Scion DTU, north of Copenhagen. To ensure optimal efficiency and flexibility, MipSalus is run by a lean core organization cooperating closely with research institutes, medical professionals, private subcontractors and others.

The company is owned by the founders and a group of private investors. In addition to funding from the owner group and co-funding from partners to joint projects, MipSalus has received grants from the Innovation Fund Denmark allowing MipSalus to accelerate the development of its drug candidate and the home sensor.

Building on its proprietary technology platform, MipSalus’ strategy is to identify and mature drug candidates and secure proof-of-concept before entering into partnerships for clinical development and commercialization.

The disease

Phenylketonuria (PKU) is a serious, congenital, lifelong metabolic disease caused by a defect in the phenylalanine hydroxylase (PAH) enzyme. The role of PAH is to break down excess phenylalanine in the body. Phenylalanine is a necessary part of the human diet and is naturally occurring in all kinds of dietary protein.

Learn More

New proprietary drug

MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia – i.e. increased level of phenylalanine in the blood), including PKU (Phenylketonuria) which makes up the vast majority of HPA patients.

MipSalus has demonstrated that the company’s phenylalanine (Phe) binding MIPs, Phelimin, very efficiently reduces the uptake of Phe from dietary proteins in PKU mice. The effect of Phelimin is dose dependent, which means that the patient has the possibility to tailor-make his or her Phelimin treatment to fit the individual meal pattern. The patient has in other words the freedom to eat small or large meals of normal food by dosing Phelimin accordingly.

Learn More
patients in the developed world
tablets per day (Current treatment)

Home sensor

MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood. Daily Phe readings would enable patients to swiftly adjust medication and food intake resulting in significant health benefits.